Clinical Trials Logo

Pediatric Kidney Disease clinical trials

View clinical trials related to Pediatric Kidney Disease.

Filter by:

NCT ID: NCT06430684 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

SGLT2I-IN-KIDS
Start date: May 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are: 1. Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)? 2. Does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests? Participants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care. Study Procedures Include - For participants randomly selected for treatment, take empagliflozin once daily for 3 months - Phone calls with researchers every 2 weeks for check-ins - For participants taking empagliflozin, clinic visits 4 and 8 weeks after starting for check-ups and tests - All study participants will have clinic visits at the beginning and end (3 months) where researchers will collect information about their health and perform tests

NCT ID: NCT06286098 Not yet recruiting - Clinical trials for Hemodialysis Complication

Alpha Lipoic Acid in Pediatrics on Hemodialysis

Start date: March 20, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to test alpha lipoic acid in children undergoing hemodialysis. The main questions it aims to answer are: - Will the use of alpha lipoic acid lower cardiovascular events in that population? - Is the incidence of those cardiovascular events linked to the oxidative stress and endothelial dysfunction in that population? - Will the drug cause side effects? Participants will: - take either one dose daily of 600mg tablet Alpha lipoic acid orally or a look-alike tablet containing no drug. - be monitored for the occurrence of cardiovascular events (stroke, angina, etc.) - be monitored for the occurrence of side effects - give blood samples for testing serum levels of E-selectin biomarker and superoxide dismutase enzyme - undergo clinical examinations (Echocardiogram, Duplex ultrasonography, Intima-Media-Thickness) Researchers will compare between the group taking alpha lipoic acid and the group taking the look-alike tablet.

NCT ID: NCT06087003 Completed - Clinical trials for Kidney Transplant Rejection

Pediatric Induction Therapy in Kidney Transplantation

PINK
Start date: March 3, 2013
Phase:
Study type: Observational

The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children. The main question it aims to answer is: Is basiliximab (anti-CD25 monoclonal antibody) induction therapy effective and safe in preventing AR after kidney transplantation in children compared with anti-thymoglobulin polyclonal antibodies induction therapy? The transplant and follow-up data of participants will be retrospectively collected. Researchers will compare the rate of AR to see if basiliximab (anti-CD25 monoclonal antibody) induction therapy is a better option for certain pediatric kidney transplant recipients.

NCT ID: NCT06057545 Recruiting - Clinical trials for Pediatric Kidney Disease

Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation

Pro-Tac
Start date: April 25, 2023
Phase: Phase 3
Study type: Interventional

Recently, a new prolonged-release tablet version of tacrolimus (Envarsus®) using the so-called MeltDose™ (US Patent No. 7,217,431) drug-delivery technology has been approved as immunosuppressive medication for patients after kidney and liver transplantation in adults but not yet in children. Studies in adults proved that Envarsus® provides the same therapeutic effectiveness as the conventional immediate-release tacrolimus formulation (Prograf®) with improved bioavailability, a more consistent pharmacokinetic profile and reduced peak to trough which might result in reduced tacrolimus dosing and subsequently reduced CNI related toxicity. Furthermore, the once daily formulation might result in improved drug adherence. The aim of this study is to assess pharmacokinetic profiles of Envarsus® as well as effectiveness and tolerability of this drug in children and adolescents ≥ 8 and ≤ 18 years of age.

NCT ID: NCT05896345 Completed - Clinical trials for Pediatric Kidney Disease

Shockwave Lithotripsy (SWL) Versus SWL and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

To conduct a RCT comparing SWL versus combined ODT and SWL as non-invasive methods for management of paediatrics radiolucent renal stone.

NCT ID: NCT05653492 Recruiting - Clinical trials for Pediatric Kidney Disease

Safety, Feasibility, and Tolerability of Sulforaphane in Children With Chronic Kidney Disease

Start date: May 15, 2023
Phase: Phase 2
Study type: Interventional

This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.

NCT ID: NCT05630729 Completed - Clinical trials for Chronic Kidney Diseases

Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management

CKD Delp
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

Leveraging a unique combination of synchronized web and mobile applications, this 3 year SBIR Phase II project will fully develop and pilot test My Kidney Guru-a program that will offer pediatric patients with CKD developmentally appropriate, interactive, and engaging instruction and practice opportunities to build knowledge and skills to manage CKD.

NCT ID: NCT05569746 Completed - Clinical trials for Pediatric Kidney Disease

A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS

Start date: October 6, 2022
Phase: Phase 2
Study type: Interventional

Hemolytic Uremic Syndrome (HUS) is a foodborne disease which mainly affects children. It is caused by Escherichia coli bacteria, which release a toxin called Shiga toxin within the body. This infectious form of HUS, defined as STEC-HUS, can cause sporadic cases or outbreaks, as observed in different countries. Argentina has the highest incidence of STEC-HUS worldwide. The disease is endemic, representing approximately 95% of all HUS cases nationwide. STEC-HUS generally begins with diarrhea (with or without blood), and can also cause fever, abdominal pain, and cramps. Then the child may have pallor, altered consciousness, decreased urine output, seizures, and other symptoms. Although death is uncommon (it occurs in 2-4% of cases), it is a very serious disease that mainly affects the kidneys, and also other organs such as the brain. About half of children need to undergo a risky procedure such as dialysis (due to malfunctioning kidneys); and most of them also receive blood transfusions. Around 30% of the patients are left with lifelong consequences that can range from permanent kidney damage to the need for a transplant. So far there is no drug, antibiotic or vaccine to prevent or treat HUS. Current treatment protocols include hospitalization for all patients with HUS, and supportive therapy such as hydration and salt intake. Support therapy is not a specific treatment, but rather helps the body better defend itself against the disease. The purpose of this study is to establish whether it is safe and effective to treat patients who are diagnosed with STEC-HUS, with INM004 (study drug). INM004 is an investigational product "Fraction F(ab')2 of Equine Shiga Antitoxin Immunoglobulin". It is a concentrated and sterile serum obtained from healthy horses immunized against Shiga toxin that contains antibodies capable of neutralizing it. The initial hypothesis is that INM004 would neutralize the entry of Shiga toxin into the body's cells thus preventing the consequent toxic damage. With the proposed treatment, INM004 would eliminate the Shiga toxin, preventing the progression of HUS symptoms and its serious complications (such as the need for and duration of dialysis, duration of hospital stays, as well as neurological, cardiovascular, intestinal complications, among others) which are associated with high morbidity and mortality. This treatment could then have an impact in health costs of STEC-HUS as well as the social costs.

NCT ID: NCT05439980 Recruiting - Clinical trials for Chronic Kidney Diseases

Improving Phosphate Control in Children With CKD

IMPACT
Start date: June 20, 2023
Phase:
Study type: Observational

Research goals: To explore the views and baseline knowledge of children and young people (CYP) with CKD and their caregivers to develop effective phosphate educational materials (PEM), adapted for age, and acknowledging different learning styles

NCT ID: NCT05388955 Completed - Clinical trials for Kidney Transplant Failure and Rejection

Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation

Start date: January 1966
Phase:
Study type: Observational

Registry study in which data of all pediatric kidney recipients in the Netherlands (registered in the Nederlandse Orgaan Transplantatie Registry) are studied to develop a risk calculator for graft loss.